Third Quarter Highlighted by Initiation of Phase 3 Study of PF614, Underscoring Progress Toward Market Readiness and Commitment to Novel Opioid Solutions ~ ~ Further Program Advancement Supported by ...

Cineverse Corp. ("Cineverse" or the "Company") (NASDAQ: CNVS), a next-generation entertainment studio, today announced its ...